Clinical trials: Leukemia, Hairy Cell
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases
RATIONALE: Studying a diagnostic biomarker test in blood samples from patients who have undergone a donor stem cell transplant for cancer may help doctors plan treatment.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia
- Trial name
- NCT00813501
- Testing
- immunosuppressive therapy, immunological diagnostic method, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Leukemia, Lymphoma
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Prostate Cancer
- Trial name
- NCT00005634
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
This clinical trial studies genetically modified peripheral blood stem cell transplant in treating patients with HIV-associated non-Hodgkin or Hodgkin lymphoma.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma
- Trial name
- NCT01769911
- Testing
- carmustine, cytarabine, melphalan
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003406
- Testing
- carboplatin, docetaxel, ifosfamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cancer Treatment Centers of America
Chronic Myeloproliferative Disorders, Leukemia
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant
RATIONALE: Questionnaires that measure coping may improve the ability to plan supportive care for patients undergoing donor bone marrow transplant.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281814
- Testing
- psychosocial assessment and care
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- The Cleveland Clinic
Leukemia, Lymphoma
Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation
RATIONALE: Peripheral blood lymphocyte therapy may be effective in the treatment and prevention of Epstein-Barr virus infection following transplantation.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005606
- Testing
- allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes, autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
- Where
- United States
- Sponsor
- Northwestern University
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Leukemia, Lymphoma
PS-341 in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced cancer.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
- Trial name
- NCT00006362
- Testing
- bortezomib
- Where
- 2 sites in United States
- Sponsor
- Mayo Clinic
Breast Cancer, Chronic Myeloproliferative Disorders
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003107
- Testing
- recombinant interleukin-12
- Where
- United States
- Sponsor
- Indiana University
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004232
- Testing
- filgrastim, cyclosporine, methylprednisolone
- Where
- United States
- Sponsor
- Northwestern University
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma
- Trial name
- NCT00004036
- Testing
- sargramostim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Leukemia, Hairy Cell
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Background: Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets CD22, a molecule on the surface of essentially all hairy cell leukemia cells.
- Trial name
- NCT01829711
- Testing
- Moxetumomab pasudotox, IV Bag Protectant for Moxetumomab pasudotox
- Where
- 34 sites in United States, Belgium and 12 more
- Volunteers
- 80 people
- Sponsor
- MedImmune LLC
Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
This phase I/Ib trial investigates the side effects of CC-486 and how well it works in combination with lenalidomide and obinutuzumab in treating patients with CD20 positive B-cell lymphoma that has come back (recurrent) or has…
- Conditions
- Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma
- Trial name
- NCT04578600
- Testing
- Lenalidomide, Obinutuzumab, Oral Azacitidine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Joseph Tuscano
Non-Hodgkin Lymphoma
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections).
- Trial name
- NCT05283720
- Testing
- Epcoritamab, Lenalidomide, Ibrutinib
- Where
- 76 sites in United States, China and 11 more
- Volunteers
- 264 people
- Sponsor
- Genmab
Cancer
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
RATIONALE: Giving donor natural killer cells to patients who have undergone donor bone marrow transplant may make the transplant work better and keep cancer cells from coming back.
- Trial name
- NCT00569283
- Testing
- therapeutic allogeneic lymphocytes
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Asan Medical Center
Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer.
- Conditions
- Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia
- Trial name
- NCT00898079
- Testing
- Cytology Specimen Collection Procedure
- Where
- 192 sites in United States, Australia and 4 more
- Volunteers
- 2,545 people
- Sponsor
- Children's Oncology Group
Leukemia
Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if giving cladribine once a day is more effective than giving cladribine once a week in…
- Trial name
- NCT00003746
- Testing
- 2-chlorodeoxyadenosine (CDA) daily, 2-chlorodeoxyadenosine weekly
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Swiss Cancer Institute
Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed).
- Trial name
- NCT06311227
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 21 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Kidney Cancer
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
RATIONALE: Light-emitting diode (LED) therapy may be able to prevent mucositis of the mouth. PURPOSE: Randomized phase II trial to determine the effectiveness of LED therapy in preventing mucositis of the mouth in children who…
- Conditions
- Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00036712
- Testing
- management of therapy complications, pain therapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Medical College of Wisconsin
Chronic Myeloproliferative Disorders, Leukemia
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Nonneoplastic Condition
- Trial name
- NCT00132015
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Institutes of Health Clinical Center (CC)